S
Sanjay Kaul
Researcher at Cedars-Sinai Medical Center
Publications - 222
Citations - 25862
Sanjay Kaul is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Randomized controlled trial & Myocardial infarction. The author has an hindex of 67, co-authored 215 publications receiving 22556 citations. Previous affiliations of Sanjay Kaul include University of California, Los Angeles & Baylor University Medical Center.
Papers
More filters
Journal ArticleDOI
Forbidden fruit: on the analysis of recurrent events in randomized clinical trials.
TL;DR: The potential limitations of this proposal are summarized and other methods to analyze recurrent events are suggested, with a particular focus on kinetic modeling, to help elucidate the causal mechanisms underlying empirical demonstrations of safety and efficacy.
Journal ArticleDOI
Augmentation of in-stent clot dissolution by low frequency ultrasound combined with aspirin and heparin. An ex-vivo canine shunt study.
Yoram Neuman,Vladimir Rukshin,Vivian Tsang,Shaul Atar,Takashi Miyamoto,Huai Luo,Sergio Kobal,Todd A. Thompson,Yochai Birnbaum,Mike Horzewski,Robert J. Siegel,Sanjay Kaul +11 more
TL;DR: Transcutaneous ultrasound significantly enhances dethrombotic effect of aspirin plus heparin on preformed stent thrombi, suggesting the potential of ultrasound as an adjunct to antithromBotic therapy to improve effectiveness without increasing the risk of bleeding complications during treatment of vascular thrombosis.
Journal Article
Beneficial antithrombotic effects of the association of pharmacological oral magnesium therapy with aspirin in coronary heart disease patients.
Michael Shechter,C. N. B. Merz,M. Paul-Labrador,Simcha R. Meisel,Robert K. Rude,Mia D. Molloy,J. H. Dwyer,P. K. Shah,Sanjay Kaul +8 more
TL;DR: A potential mechanism whereby magnesium may beneficially alter outcomes in patients with CAD is suggested, which appears to be independent of platelet aggregation or P-selectin expression, and is evident despite aspirin therapy.
Journal ArticleDOI
Bayes Factor Meta-Analysis of the Mortality Claim for Peripheral Paclitaxel-Eluting Devices
TL;DR: This study finds some support for increased mortality after using paclitaxel-eluting devices in femoropopliteal arterial disease, but the evidence is not unequivocal and may not sway skeptical investigators concerned about causation, unreported studies, or the post hoc analysis of trials underpowered for mortality.